V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310004182 | 310001801 | 0 | 45.2 | Not known (9) | 2014-04-25 | 2014-04-25 | Dacarbazine | N | null | 310019397 | CAPECITABINE + CISPLATIN |
| 310004183 | 310001802 | 1.65 | 79.6 | null | 2017-08-29 | 2017-08-29 | CHOEP - 21 days | N | N | 310019398 | CHOEP |
| 310004184 | 310001803 | 1.82 | 91.5 | Curative (C) | 2016-08-13 | 2016-08-13 | ICON8 TRIAL | 2 | N | 310019399 | LIPOSOMAL DOXORUBICIN |
| 310004185 | 310001804 | 1.67 | 70 | Palliative (P) | 2016-08-11 | 2016-08-10 | Liposomal Doxorubicin (20mg/m2) | N | N | 310019400 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004186 | 310001805 | 1.72 | 114.4 | Neo-adjuvant (N) | 2015-08-09 | 2015-08-16 | BEVACIZUMAB + CARBO + PACLITAXEL | N | N | 310019404 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004187 | 310001806 | null | null | 4 | 2017-05-20 | 2017-05-21 | Bexarotene | 2 | null | 310019407 | CAPECITABINE + CISPLATIN |
| 310004188 | 310006775 | 1.63 | 91.5 | Disease modification (D) | 2015-02-26 | 2015-02-28 | Dacarbazine | N | N | 310019409 | CISPLATIN + FLUOROURACIL |
| 310004189 | 310009150 | null | -1 | Neo-adjuvant (N) | 2014-05-13 | 2014-05-17 | Capecitabine + Cisplatin | 02 | N | 310019411 | IMATINIB |
| 310004190 | 310009150 | 1.57 | 53.4 | Neo-adjuvant (N) | 2016-03-22 | 2016-03-30 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | 310019411 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004191 | 310009150 | 1.88 | 0 | Palliative (P) | 2016-10-24 | 2016-10-29 | Dacarbazine | null | N | 310019411 | HYDROXYCARBAMIDE |
| 310004192 | 310011456 | 0 | 77.9 | Curative (C) | 2015-09-12 | 2015-09-20 | Rituximab | N | N | 310019418 | CISPLATIN + FLUOROURACIL |
| 310004193 | 310011456 | 1.8 | 59.3 | Neo-adjuvant (N) | 2017-08-02 | 2017-08-03 | Vemurafenib | 02 | N | 310019418 | BEXAROTENE |
| 310004194 | 310011456 | 1.63 | null | Disease modification (D) | 2015-07-08 | 2015-07-17 | Dacarbazine | N | N | 310019418 | MITOMYCIN INTRAVESICULAR |
| 310004195 | 310011456 | 1.86 | 82.6 | Neo-adjuvant (N) | 2015-08-09 | 2015-08-10 | Hydroxycarbamide | 02 | N | 310019418 | EOX |
| 310004196 | 310001807 | null | null | null | null | 2015-06-16 | ECX | N | N | 310019423 | ECX |
| 310004197 | 310001807 | 1.72 | 101 | Palliative (P) | 2016-06-05 | 2016-06-06 | IPILIMUMAB + NIVOLUMAB | 2 | N | 310019423 | IPILIMUMAB + NIVOLUMAB |
| 310004198 | 310009151 | 1.75 | null | Palliative (P) | 2015-01-29 | 2015-01-30 | IPILIMUMAB + NIVOLUMAB | N | null | 310019425 | IPILIMUMAB + NIVOLUMAB |
| 310004199 | 310009151 | 1.86 | null | Curative (C) | 2017-02-14 | 2017-02-24 | CHOEP - 14 days | 2 | N | 310019425 | CHOEP |
| 310004200 | 310009151 | null | null | Palliative (P) | null | 2014-03-21 | Capecitabine + Cisplatin | N | N | 310019425 | BEXAROTENE |
| 310004201 | 310009151 | 0 | 81.5 | null | 2013-03-13 | 2013-03-20 | CHOEP - 21 days | 02 | N | 310019425 | CHOEP |
| 310004202 | 310009151 | 1.73 | 69.2 | Palliative (P) | 2017-08-12 | 2017-09-18 | Capecitabine + Cisplatin | N | null | 310019425 | ICON TRIAL |
| 310004203 | 310009151 | 1.86 | 101 | Palliative (P) | null | 2018-02-17 | CAPECITABINE + OXALIPLATIN | null | null | 310019425 | VEMURAFENIB |
| 310004204 | 310009151 | 1.77 | 0 | Disease modification (D) | 2016-06-07 | 2016-06-14 | CHOEP - 21 days | N | N | 310019425 | CHOEP |
| 310004205 | 310001808 | null | null | null | 2014-10-26 | 2014-10-26 | EOX | N | N | 310019440 | BEXAROTENE |
| 310004206 | 310001808 | 1.77 | 104 | Palliative (P) | 2017-06-06 | 2017-06-13 | ECX | 02 | N | 310019440 | ECX |
| 310004207 | 310001809 | 1.68 | 71.1 | Neo-adjuvant (N) | 2016-12-01 | 2016-12-02 | Bexarotene | N | null | 310019446 | HYDROXYCARBAMIDE |
| 310004208 | 310006778 | null | 76 | Radical (R) | 2015-11-02 | 2015-11-06 | EOX | N | N | 310019447 | OXALIPLATIN + MDG |
| 310004209 | 310001810 | 1.52 | 100.7 | Disease modification (D) | 2010-08-18 | 2015-04-18 | EOX | 02 | N | 310019449 | GEMCITABINE + PACLITAXEL |
| 310004210 | 310001810 | 1.7 | 37.9 | Curative (C) | 2017-05-05 | 2017-05-11 | NB HRNBL-1 COJEC Ind COURSE A | N | N | 310019449 | NOT MATCHED |
| 310004211 | 310001810 | 1.67 | 77.7 | null | 2015-01-25 | 2015-02-09 | ICON8 TRIAL | null | null | 310019449 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004212 | 310001810 | 1.71 | 72 | Palliative (P) | 2018-01-14 | 2018-01-17 | Bevacizumab+Carbo+Pacliaxel | N | N | 310019449 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 310004213 | 310001811 | 1.72 | 72.2 | Curative (C) | 2015-12-18 | 2015-12-18 | Dacarbazine | 2 | N | 310019457 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004214 | 310001812 | null | 74 | Palliative (P) | 2016-09-07 | 2016-09-08 | Vemurafenib | null | N | 310019460 | PACLITAXEL |
| 310004215 | 310001813 | null | null | Curative (C) | 2013-06-03 | 2013-06-10 | Hydroxycarbamide | N | N | 310019462 | CISPLATIN + FLUOROURACIL |
| 310004216 | 310001814 | null | null | Palliative (P) | 2013-05-15 | 2013-06-03 | ECX | 02 | N | 310019463 | ECX |
| 310004217 | 310001814 | 1.72 | 92.3 | Curative (C) | 2013-07-26 | 2013-07-26 | Mitomycin Intravesical | 02 | N | 310019463 | PACLITAXEL |
| 310004218 | 310001815 | null | 73.9 | Curative (C) | 2015-06-30 | 2015-07-15 | GEM-P | N | N | 310019466 | DACARBAZINE |
| 310004219 | 310001815 | 1.74 | 72 | Disease modification (D) | 2013-11-11 | 2013-11-11 | Capecitabine + Cisplatin | N | N | 310019466 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004220 | 310001816 | 1.68 | 84.4 | Palliative (P) | 2016-02-27 | 2016-03-01 | ECX | N | N | 310019469 | ECX |
| 310004221 | 310001817 | 1.84 | 80.5 | Palliative (P) | 2015-06-19 | 2015-07-15 | Vemurafenib | 02 | N | 310019470 | OXALIPLATIN + MDG |
| 310004222 | 310006782 | 1.75 | 69.4 | Neo-adjuvant (N) | 2016-02-28 | 2016-03-06 | CISPLATIN + FLUOROURACIL | Y | N | 310019471 | EOX |
| 310004223 | 310006782 | 1.8 | 88.4 | null | 2015-03-20 | 2015-03-22 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 310019471 | CISPLATIN + FLUOROURACIL |
| 310004224 | 310001818 | 1.63 | 65 | Neo-adjuvant (N) | 2013-08-09 | 2013-08-09 | ECX | 02 | N | 310019474 | ECX |
| 310004225 | 310006783 | 1.67 | 0 | null | 2015-07-06 | 2015-07-06 | Cisplatin +Fluorouracil (3 wk) | N | N | 310019475 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 310004226 | 310006783 | 1.47 | null | null | 2013-05-26 | 2013-06-20 | CISPLATIN + FLUOROURACIL | N | N | 310019475 | VEMURAFENIB |
| 310004227 | 310006783 | 1.6 | 8.1 | Palliative (P) | 2016-11-30 | 2016-12-17 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | 310019475 | CISPLATIN + FLUOROURACIL |
| 310004228 | 310001819 | 1.19 | null | Neo-adjuvant (N) | 2015-08-13 | 2015-09-03 | ECX | N | N | 310019479 | ECX |
| 310004229 | 310001820 | 1.78 | 93 | Palliative (P) | null | 2017-07-19 | ECX | 2 | N | 310019480 | DACARBAZINE |
| 310004230 | 310001821 | 1.63 | null | Palliative (P) | 2016-02-10 | 2016-02-17 | IPILIMUMAB + NIVOLUMAB | N | N | 310019481 | IPILIMUMAB + NIVOLUMAB |
| 310004231 | 310001821 | 1.6 | 75 | null | 2013-10-04 | 2013-10-05 | EOX | 02 | N | 310019481 | CISPLATIN + FLUOROURACIL |